Compounds / Longevity / Cardiogen

Cardiogen

Cardiogen (Ala-Glu-Asp-Arg tetrapeptide)
LongevityFDA: Not approved — not evaluated by FDA

Overview

Synthetic tetrapeptide bioregulator from St. Petersburg Institute. Russian studies suggest cardioprotective effects via gene expression modulation. Claimed reduction in cardiovascular mortality in elderly cohorts over 12-15 year follow-up.

Mechanism of Action

Khavinson bioregulatory peptide targeting cardiac tissue gene expression. Proposed to modulate cardiomyocyte genes involved in remodeling, apoptosis inhibition, and antioxidant defense.

Molecular Profile

Molecular weight
461.5 Da

Key Research Findings

Khavinson peptide series; cardiac tissue targeting; Russian clinical data; limited Western peer review.

Published Research

Advances in Gerontology
Peptide bioregulators: a new class of geroprotectors
View source
Bull Exp Biol Med
Peptide regulation of gene expression in cardiac muscle
View source

Related Longevity Compounds

GHK-CuEpithalonMOTS-cSS-31FOXO4-DRINAD+
Clinical Guidance

Research data is not a treatment plan. If you are considering Cardiogen, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Cardiogen? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals